A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Institut Bergonié
Odense University Hospital
UNICANCER
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)